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ESMO Clinical Recommendations: using
the easier and faster approach to
oncology guidelines
the original idea
The European Society for Medical Oncology (ESMO) has
developed and disseminated clinical recommendations to all
European and non-European oncologists. ESMO’s motivation
was to establish the clinical recommendations, as it was felt they
were important for the future development of medical
oncology and for achieving high common standards of medical
practice for patients in all European countries.
The principles of the ESMO clinical recommendations were:
(i) to create a set of statements for an essential standard of care;
(ii) to be disease or topic oriented; (iii) to be evidence based;
(iv) to have an emphasis on medical oncology; and (v) to be
annually updated.
Each of the ESMO clinical recommendations provides vital,
evidence-based information for physicians, including the
incidence of the malignancy, diagnostic criteria, staging of
disease and risk assessment, treatment plans and follow-up.
the history
1998
The original idea for the creation of the ESMO clinical
guidelines came from Professor Heine H. Hansen via the
Central European Task Force in 1998. In particular, he
visualized the need for clinical recommendations that might be
more practical in daily use. This was supported at a meeting of
the ESMO national representatives, who felt that the
development of guidelines would contribute to the standing of
medical oncology in Europe.
1999
Thus, in 1999 the ESMO Guidelines Task Force was
constituted. Initially, the group began with a chairman (Rolf
Stahel, Switzerland), a central coordinator (Lorez Jost,
Switzerland), an ESMO officer (Maria Cristina Reinhart) and
five members (Jørn Herrstedt, Denmark; Otto Kloke, Germany;
Nicholas Pavlidis, Greece; Gunta Purkalne, Latvia; and Svetislav
Jelic, Yugoslavia). During the next 5 years more members
joined the task force (Jonas Bergh, Sweden; Richard Greil,
Austria; Vesa Kataja, Finland; and Joa˜o Oliveira, Portugal).
2006
Since 1 January 2006 the Guidelines Task Force has been an
independent group—the ESMO Guidelines Working
Group—under the new ESMO Education Committee structure.
It consists of: (i) an editorial board with a chairman (Nicholas
Pavlidis, Greece), three members (Rolf Stahel, Switzerland;
Heine Hansen, Denmark; and Svetislav Jelic, Serbia), an Annals
of Oncology executive (Lewis Rowett, UK) and an ESMO
Coordinator (Paola Minotti, Switzerland), (ii) the seven subject
editors responsible for the topics, the authors, the revision of
the manuscripts and the presentation and discussion of final
drafts with the editorial board (M. Castiglione, Switzerland;
J. Oliveira, Portugal; E. Felip, Spain; V. Kataja, Finland;
M. Dreyling, Germany; L. Jost, Switzerland; and F. Roila, Italy),
(iii) the assigned authors and (iv) the five preselected reviewers
per topic who have all been ESMO Faculty members.
2008
In 2008 the Guidelines Working Group made some changes
and now consists of: (i) an editorial board with a chairman
(Nicholas Pavlidis, Greece), two members (Rolf Stahel,
Switzerland and Heine Hansen, Denmark), an Annals of
Oncology executive (Lewis Rowett, UK), an external medical
oncologist coordinator (George Pentheroudakis, Greece) and
an ESMO Coordinator (Roberta Vecchi, Switzerland); (ii) nine
subject editors: Monica Castiglione—Switzerland for breast and
gynaecological cancer, Martin Dreyling—Germany for
haematological malignancies, Enriqueta Felip—Spain for
lung and head/neck cancer, Paolo Casali—Italy for
sarcomas, Vesa Kataja—Finland for genito-urinary cancer,
Andres Cervantes—Spain for gastrointestinal cancer,
Fausto Roila—Italy for supportive care, Svetislav
Jelic—Serbia for liver, pancreatic cancer and neuroendocrine
tumours and George Pentheroudakis—Greece for rare
tumours; (iii) the assigned authors and (iv) the five preselected
reviewers per topic on a multidisciplinary platform (Figure 1).
Figure 2 demonstrates the functioning network of the ESMO
Guidelines Working Group
Nearly 9 years after the inception of the ESMO Guidelines
Task Force and up to 2009, 54 clinical recommendations were
freely available on the ESMO website and in Annals of
Oncology.
the evaluation of dissemination of
ESMO Clinical Recommendations
During the last several years ESMO Clinical Recommendations
have been disseminated and implemented through different
methodological tools.
We continuously evaluate the results of these tools in order
to access the diffusion of ESMO Clinical Recommendations to
the oncological community.
These tools are: (i) the data from the annual downloads of
Oxford Journals usage statistics through the supplementary
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issues of Annals of Oncology, (ii) the evaluation scoring from
the interactive ESMO Guidelines sessions conducting during
the ESMO Congresses and (iii) the results from a questionnaire
(with 10 questions related to ESMO Guidelines evaluation)
distributed to ESMO Congresses and ECLU participants.
downloads
The extracted data from the downloads for the last 2 years were
the following:
(i) May 2007–May 2008: 45 066 and (ii) May 2008–October
2008: 60 330 downloads (Table 1). The three most commonly
downloaded tumours were ‘primary breast cancer’, ‘metastatic
breast cancer’ and ‘non-small-cell lung cancer’.
interactive ESMO sessions
The evaluation scoring (average score) of the five interactive
sessions during the last five ESMO Congresses were as follow:
Hamburg (2000): 3.78, Nice (2002): 4.05, Vienna (2004): 4.07,
Istanbul (2006): 4.24 and Stockholm (2008): 4.48 (Table 2).
the questionnaire
Analysis of the questionnaire data from the 31st and 32nd
ESMO Congresses and the2007 and 2008 ECLU conferences
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Figure 2. The operational network of the ESMO Guidelines Working
Group.
Table 1. Downloads extracted data
Period No. of downloads
May 2007–May 2008 (12 months) 45 066
May 2008–October 2008 (6 months) 60 330
Table 2. Evaluation of ESMO interactive GL sessions
Date and place
of congress
Topics discussed Average score (1–5)
2000, Hamburg Colon cancer 3.78
NSCLC
Testicular cancer
2002, Nice CUP 4.05
Ovarian cancer
Prostate cancer
2004, Vienna Advanced breast cancer 4.07
Follicular lymphoma
Rectal cancer
2006, Istanbul Breast cancer (adjuvant) 4.24
NSCLC
Hodgkin’s lymphoma
2008, Stockholm Thrombosis and cancer 4.48
Pregnancy and cancer
Gastric cancer
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showed that the majority of the European and non-European
oncologists favor ESMO Clinical Recommendations (Table 3).
the perspectives
The ESMO Guidelines Working Group feels that the ESMO
Clinical Recommendations have been widely accepted by the
oncological community.
It should also be emphasized that ESMO Clinical
Recommendations have already been translated into nine
languages (French, German, Italian, Spanish, Portuguese,
Russian, Japanese, Chinese and Greek).
Since last year the ESMO Guideline Task Force decided to
include a number of clinical recommendations as a product of
International Consensus Conferences. These recommendations
will be larger in context and more detailed than the previously
existing ESMO Guidelines.
In addition, the ESMO Guidelines Working Group intends
in the near future to increase the size of several clinical
recommendations, especially those of the most common
tumours (the big killers), due to a continuous huge amount of
new information.
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Table 3. Data from ESMO Guidelines questionnaire analysis (%)
31st ESMO
Istanbul
2006
ECLU
Lugano
2007
ECLU
Lugano
2008
32nd ESMO
Stockholm
2008
Do you think ESMO
CRs are a helpful
source of advice? (YES)
80.8 90.7 87 71
Do you think
ESMO CRs are good
educational tools? (YES)
84.9 90.4 88 72
Do you think ESMO
CRs are intended to
improve quality of
care ? (YES)
94.1 91.5 87 84
Do you think ESMO
CRs reduce physicians
autonomy and are
oversimplified or
‘cook-book medicine’? (NO)
74.3 59.2 60 63
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